Prelude reports Q3 2026 results, advances KAT6A and JAK2V617F programs
Prelude says cash runway now extends into the second quarter of 2028 as its PRT13722 and PRT12396 trials continue enrolling.
Prelude Therapeutics reported third quarter 2026 financial results and a pipeline update on November 16, 2026. The company initiated enrollment into its Phase 1 study of PRT13722 in HR+ breast cancer in the fourth quarter of 2026 and anticipates disclosure of initial proof of concept data from the study in the second half of 2027.1 PRT13722 is an oral KAT6A selective degrader that received FDA clearance to proceed under its Investigational New Drug Application in September 2026.1
In October 2026, Prelude entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company for supply of abemaciclib and imlunestrant, supporting evaluation of PRT13722 in combination with those agents in the existing Phase 1 trial in HR+/HER2- breast cancer patients.1
PRT12396, Prelude's mutant-selective JAK2V617F inhibitor, continues enrolling patients in a Phase 1 study in polycythemia vera and myelofibrosis.1 That program remains subject to an exclusive option agreement with Incyte announced in November 2025, set to expire in February 2027 with potential for a three month extension.1
The company also disclosed upcoming scientific presentations. A Trials in Progress abstract on the PRT12396 study has been accepted for poster presentation at the American Society of Hematology 67th Annual Meeting, taking place in New Orleans, LA, December 12-15, 2026.1 Prelude's mCALR degrader antibody conjugate data presentation timing is described inconsistently in the release: the summary bullet cites acceptance for presentation at the American Society of Hematology (ASH) 68th Annual Meeting in December1, while the program section states updated preclinical data from the leading development candidate has been accepted for poster presentation at the American Society of Hematology (ASH) 67th Annual Meeting taking place in New Orleans, LA December 12-15, 2026.1
On finances, cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026 were $142.7 million1, and the company anticipates this will fund operations into the second quarter of 2028.1 Net loss for the three months ended September 30, 2026 was $12.5 million, or $0.12 per share, compared to $19.7 million, or $0.26 per share, for the prior year period.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.